
ORR is an actively managed ETF aiming for capital appreciation through both long and short equity positions. The long portfolio targets undervalued or growth potential equities, with a focus on developed markets. Long positions may exceed 100% of net assets, capped typically at 150%. Short positions focus on U.S.-listed companies and ETFs expected to decline, influenced by declining future cash flow projections. ORR can have short exposure up to 100% and may include inverse or leveraged ETFs. The fund actively trades positions, resulting in high annual portfolio turnover. The portfolio may also short foreign currencies through currency forward contracts to manage risk.
Is ORR's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.

[url="]Genmab A/S[/url] (Nasdaq: GMAB) today announced new data from two studies evaluating epcoritamab, a T-cell engaging antibody administered subcutaneously

New TALVEYÂ (talquetamab-tgvs) plus DARZALEX FASPROÂ (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combi

[url="]BeOne Medicines Ltd.[/url] (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 datas

IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Li

Militia Long/Short Equity ETF offers retail investors access to a diversified, actively managed global long/short equity strategy, typically reserved for hedge funds. ORR's early performance is strong, with a 31.63% return since inception and a low portfolio beta of 0.43, despite high gross exposure. The fund employs a sophisticated portfolio construction, balancing global long positions with index and structural shorts for factor diversification.